How Evaluate Supports Your Success
By applying machine learning to millions of data points from across the full clinical pipeline – including early phase and privately held assets – Evaluate Omnium identifies key risk and return correlations that uncover unique, highly accurate insights into asset development and commercial opportunity
Unlock deeper insights and make business-critical investment decisions with greater confidence. Evaluate Omnium allows you to:
1
Risk and return landscape overview
Leverage predicted NPV by indication that covers 8x more NPV models for R&D programmes that aren’t usually covered by existing consensus forecasts. Improve your understanding of product value drivers.
2
Risk-adjusted peak sales and ROI benchmarks
Combine product-specific PTRS and predicted peak sales analytics to provide a single metric for forecasting the commercial potential of different pharma assets across all phases of clinical development. Predict ROI at product indication, product, and company level.
3
Risk and return landscape overview
Leverage NPV by indication that covers 8x more NPV models for R&D programmes that aren’t usually covered by existing consensus forecasts. Improve your understanding of product value drivers.
